AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#TBD) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

This Study is
No Longer Enrolling

Details
Age

Child to Adult

Type of Study

Treatment

Locations

Childrens Hospital Colorado

Study ID

Protocol Number: 17-1086

More information available at ClinicalTrials.gov: NCT02981628

Categories

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers